Article
A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma.
Cancer research - 15 Oct 2001
Iughetti P, Suzuki O, Godoi P H, Alves V A, Sertié A L, Zorick T, Soares F, Camargo A, Moreira E S, di Loreto C, Moreira-Filho C A, Simpson A, Oliva G, Passos-Bueno M R
Abstract excerpt
We have performed association studies between a novel coding single nucleotide polymorphism (D104N) in endostatin, one of the most potent inhibitors of angiogenesis, and prostate cancer. We observed that heterozygous N104 individuals have a 2.5 times increased chance of developing prostate cancer as compared with homozygous D104 subjects (odds ratio, 2.4; 95% confidence interval, 1.4-4.16). Modeling of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.